company background image
603387 logo

Getein Biotech SHSE:603387 Stock Report

Last Price

CN¥7.63

Market Cap

CN¥3.9b

7D

-1.0%

1Y

-38.6%

Updated

19 Jul, 2024

Data

Company Financials

603387 Stock Overview

Researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally.

603387 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends4/6

Getein Biotech, Inc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Getein Biotech
Historical stock prices
Current Share PriceCN¥7.63
52 Week HighCN¥12.80
52 Week LowCN¥7.27
Beta0.16
11 Month Change-6.50%
3 Month Change-11.59%
1 Year Change-38.57%
33 Year Change-48.17%
5 Year Change-41.12%
Change since IPO-8.52%

Recent News & Updates

Getein Biotech (SHSE:603387) Is Due To Pay A Dividend Of CN¥0.10

Jun 07
Getein Biotech (SHSE:603387) Is Due To Pay A Dividend Of CN¥0.10

Recent updates

Getein Biotech (SHSE:603387) Is Due To Pay A Dividend Of CN¥0.10

Jun 07
Getein Biotech (SHSE:603387) Is Due To Pay A Dividend Of CN¥0.10

Shareholder Returns

603387CN BiotechsCN Market
7D-1.0%2.1%-0.4%
1Y-38.6%-19.8%-17.0%

Return vs Industry: 603387 underperformed the CN Biotechs industry which returned -19.8% over the past year.

Return vs Market: 603387 underperformed the CN Market which returned -17% over the past year.

Price Volatility

Is 603387's price volatile compared to industry and market?
603387 volatility
603387 Average Weekly Movement4.2%
Biotechs Industry Average Movement6.1%
Market Average Movement5.9%
10% most volatile stocks in CN Market9.1%
10% least volatile stocks in CN Market4.0%

Stable Share Price: 603387's share price has been volatile over the past 3 months.

Volatility Over Time: 603387's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20022,508n/awww.getein.com.cn

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection of cardiac troponin I, chemiluminescence, biochemical detection, molecular detection, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, thrombosis and hemostasis, and other technical fields, covering cardiovascular, inflammation, kidney, thyroid function, hormone, glucose metabolism, tumor, blood cells, blood coagulation, and other detection fields. Its product applications include laboratory departments of medical institutions, emergency rooms, health examination center, community clinic, family personal health management, etc. The company was founded in 2002 and is headquartered in Nanjing, China.

Getein Biotech, Inc Fundamentals Summary

How do Getein Biotech's earnings and revenue compare to its market cap?
603387 fundamental statistics
Market capCN¥3.87b
Earnings (TTM)CN¥244.26m
Revenue (TTM)CN¥1.31b

15.8x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
603387 income statement (TTM)
RevenueCN¥1.31b
Cost of RevenueCN¥447.97m
Gross ProfitCN¥858.46m
Other ExpensesCN¥614.20m
EarningsCN¥244.26m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 29, 2024

Earnings per share (EPS)0.48
Gross Margin65.71%
Net Profit Margin18.70%
Debt/Equity Ratio22.7%

How did 603387 perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

88%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.